Literature DB >> 15183541

Proteomic phenotyping: metastatic and invasive breast cancer.

Yetrib Hathout1, Marion L Gehrmann, Andrei Chertov, Catherine Fenselau.   

Abstract

The adriamycin resistant breast cancer cell line (MCF-7/ADR) is a subject of ongoing debate concerning its origin and or source. Previous studies in our laboratory showed that MCF-7/ADR has a unique cytosolic protein expression pattern when compared to that of the parental MCF-7 cell line and other drug resistant MCF-7 cell lines. Protein expression patterns obtained using two-dimensional gel electrophoresis and mass spectrometry indicated that this MCF-7/ADR cell line shares some similarities with the metastatic breast cancer cell lines MDA-MB. Further comparisons with available two-dimensional gel electrophoresis maps in the literature indicate that MCF-7/ADR has a protein expression signature even closer to of the ductal infiltrating breast carcinoma cell line 8701. These observations suggest that MCF-7/ADR cells might have originated in a selection of ductal infiltrating carcinoma cells, which were present among the original MCF-7 cell population. These ductal infiltrating carcinoma cells may possess an intrinsic adriamycin resistance phenotype. Copyright 2004 Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15183541     DOI: 10.1016/j.canlet.2004.01.019

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

1.  Glycomic profiling of invasive and non-invasive breast cancer cells.

Authors:  John A Goetz; Yehia Mechref; Pilsoo Kang; Meei-Huey Jeng; Milos V Novotny
Journal:  Glycoconj J       Date:  2008-08-28       Impact factor: 2.916

Review 2.  Proteomic analysis in cancer research: potential application in clinical use.

Authors:  Jesús García-Foncillas; Eva Bandrés; Ruth Zárate; Natalia Remírez
Journal:  Clin Transl Oncol       Date:  2006-04       Impact factor: 3.405

3.  Identification of CD44 as a surface biomarker for drug resistance by surface proteome signature technology.

Authors:  Jason W Cain; Robert S Hauptschein; Jean K Stewart; Tugba Bagci; Gary G Sahagian; Daniel G Jay
Journal:  Mol Cancer Res       Date:  2011-02-25       Impact factor: 5.852

Review 4.  A systems biology approach to defining metastatic biomarkers and signaling pathways.

Authors:  Natalie E Goldberger; Kent W Hunter
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2009 Jul-Aug

5.  MCF-7/ADR cells (re-designated NCI/ADR-RES) are not derived from MCF-7 breast cancer cells: a loss for breast cancer multidrug-resistant research.

Authors:  Weifeng Ke; Pei Yu; Jianfeng Wang; Ruitao Wang; Chongyong Guo; Ling Zhou; Changchun Li; Ke Li
Journal:  Med Oncol       Date:  2010-11-30       Impact factor: 3.064

Review 6.  Integrated gene networks in breast cancer development.

Authors:  Ivana Ratkaj; Emil Stajduhar; Srdan Vucinic; Sime Spaventi; Hrvojka Bosnjak; Kresimir Pavelic; Sandra Kraljevic Pavelic
Journal:  Funct Integr Genomics       Date:  2010-02-04       Impact factor: 3.410

7.  Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins.

Authors:  Jana Mladkova; Miloslav Sanda; Eva Matouskova; Irena Selicharova
Journal:  BMC Cancer       Date:  2010-08-23       Impact factor: 4.430

Review 8.  Application of proteomics in the study of tumor metastasis.

Authors:  Zhen Cai; Jen-Fu Chiu; Qing-Yu He
Journal:  Genomics Proteomics Bioinformatics       Date:  2004-08       Impact factor: 7.691

9.  Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype.

Authors:  Changhua Zhou; Ashley M Nitschke; Wei Xiong; Qiang Zhang; Yan Tang; Michael Bloch; Steven Elliott; Yun Zhu; Lindsey Bazzone; David Yu; Christopher B Weldon; Rachel Schiff; John A McLachlan; Barbara S Beckman; Thomas E Wiese; Kenneth P Nephew; Bin Shan; Matthew E Burow; Guangdi Wang
Journal:  Breast Cancer Res       Date:  2008-12-16       Impact factor: 6.466

10.  Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer.

Authors:  Liping Chung; Katrina Moore; Leo Phillips; Frances M Boyle; Deborah J Marsh; Robert C Baxter
Journal:  Breast Cancer Res       Date:  2014-06-16       Impact factor: 6.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.